AIM: To investigate the expression and potential prognostic role of vascular endothelial growth factor (VEGF) and endoglin in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). METHODS: Microvessel density (MVD) in GEP-NETs was evaluated using endoglin and CD31 immunohistochemistry. In addition, tissue levels of endoglin and VEGF were determined in homogenates by ELISA. RESULTS: Endoglin was highly expressed on tumor endothelial cells. CD31 MVD in GEP-NETs was significantly higher compared to endoglin MVD (P < 0.01). Two- to four-fold higher tissue levels of endoglin and VEGF were seen in tumors compared to associated normal tissue. This increased endoglin tissue expression in tumors was significantly related to tumor size (P < 0.01), presence of metastases (P = 0.04), and a more advanced tumor stage (P = 0.02), whereas expression of VEGF was not. CONCLUSION: We suggest that endoglin is a potential marker to indicate and predict metastases, which might be useful in the post-resection therapeutic approach of patients with GEP-NETs.
AIM: To investigate the expression and potential prognostic role of vascular endothelial growth factor (VEGF) and endoglin in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). METHODS: Microvessel density (MVD) in GEP-NETs was evaluated using endoglin and CD31 immunohistochemistry. In addition, tissue levels of endoglin and VEGF were determined in homogenates by ELISA. RESULTS:Endoglin was highly expressed on tumor endothelial cells. CD31 MVD in GEP-NETs was significantly higher compared to endoglin MVD (P < 0.01). Two- to four-fold higher tissue levels of endoglin and VEGF were seen in tumors compared to associated normal tissue. This increased endoglin tissue expression in tumors was significantly related to tumor size (P < 0.01), presence of metastases (P = 0.04), and a more advanced tumor stage (P = 0.02), whereas expression of VEGF was not. CONCLUSION: We suggest that endoglin is a potential marker to indicate and predict metastases, which might be useful in the post-resection therapeutic approach of patients with GEP-NETs.
Authors: Lukas J A C Hawinkels; Patricia Kuiper; Eliza Wiercinska; Hein W Verspaget; Zhen Liu; Evangelia Pardali; Cornelis F M Sier; Peter ten Dijke Journal: Cancer Res Date: 2010-04-27 Impact factor: 12.701
Authors: L J A C Hawinkels; H W Verspaget; W van Duijn; J M van der Zon; K Zuidwijk; F J G M Kubben; J H Verheijen; D W Hommes; C B H W Lamers; C F M Sier Journal: Br J Cancer Date: 2007-07-17 Impact factor: 7.640
Authors: Marcos Vinícius Macedo de Oliveira; Carlos Alberto de Carvalho Fraga; Lucas Oliveira Barros; Camila Santos Pereira; Sérgio Henrique Sousa Santos; John R Basile; Ricardo Santiago Gomez; André Luiz Sena Guimarães; Alfredo Maurício Batista De-Paula Journal: Clin Exp Metastasis Date: 2014-05-06 Impact factor: 5.150
Authors: Lidia Kędzierska; Anna Madej-Michniewicz; Natalia Marczuk; Barbara Dołęgowska; Teresa Starzyńska; Wojciech Błogowski Journal: Am J Transl Res Date: 2020-01-15 Impact factor: 4.060